In an interview with PharmaShots, Manos Perros shares his views on the data from the P-III (ATTACK) trial of sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant acinetobacter infectionsShots:The P-III ATTACK trial evaluates SUL-DUR vs colistin in 207 patients with infections caused by Acinetobacter baumannii at 95 clinical sites in 17 countriesThe trial met its 1EPs i.e., patients achieved non-inferiority in 28-day all-cause…
